Download The Case Study
Successful approaches from recent cell and gene therapy product approval
Successful approaches from recent cell and gene therapy product approval
Global Rare Blood Disorder Study Achieves Market Approval and 100% Patient Retention
In a newly-released case study, Medpace cell and gene therapy experts review the challenges and solutions to this open-label, single-dose, multicenter, multinational trial.
Download the new case study to explore successful approaches from the recent cellular and gene therapy product approval:
Cell and Gene Therapy
An integrated Approach
Medpace has contributed to over 130 CGT (cell and gene therapy) trials, including advancement through marketing authorization approval. This depth of experience highlights our ability to manage the most complex and innovative advanced therapy trials. Gain the Medpace advantage:
- Dedicated CGT experts for clinical trial delivery—across numerous therapeutic areas and global regions including Asia Pacific, Europe, and the US—demonstrated by 130+ cell and gene therapy trials
- Comprehensive regulatory affairs and operational experts who work collaboratively with our medical team
- Integrated laboratory services, providing an array of CGT lab capabilities for cohesive, streamlined, and standardized trial management
